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Protein degradation via the use of bivalent chemical
degraders provides an alternative strategy to block
protein function and assess the biological roles of
putative drug targets. This approach capitalizes on
the advantages of small-molecule inhibitors while
moving beyond the restrictions of traditional phar-
macology. Here, we report a chemical degrader
(UNC6852) that targets polycomb repressive com-
plex 2 (PRC2). UNC6852 contains an EED226-
derived ligand and a ligand for VHL which bind to
the WD40 aromatic cage of EED and CRL2VHL,
respectively, to induce proteasomal degradation
of PRC2 components, EED, EZH2, and SUZ12.
Degradation of PRC2 with UNC6852 blocks the
histone methyltransferase activity of EZH2,
decreasing H3K27me3 levels in HeLa cells and
diffuse large B cell lymphoma (DLBCL) cells con-
taining EZH2 gain-of-function mutations. UNC6852
degrades both wild-type and mutant EZH2, and
additionally displays anti-proliferative effects in
this cancer model system.
INTRODUCTION
Polycomb repressive complex 2 (PRC2) is a multicomponent
complex with histone methyltransferase (HMT) activity that in-
stalls and maintains mono- through trimethylation at histone 3
lysine 27 (H3K27). H3K27 trimethylation (H3K27me3) is a key
mechanism responsible for gene repression (Ferrari et al.,
2014). The catalytic activity of PRC2 is dependent on the forma-
tion of a complex containing three core subunits: embryonic
ectoderm development (EED), enhancer of zeste homolog 1(EZH1) or EZH2, and suppressor of zeste homolog 12 (SUZ12)
(Margueron and Reinberg, 2011). EZH1 and EZH2 share signifi-
cant sequence homology and both HMTs can be incorporated
into PRC2 to generate an active complex; however, EZH1 has
a lower abundance and often lesser HMT activity compared
with EZH2 (Margueron et al., 2008; Lee et al., 2018). Other pro-
teins commonly associated with PRC2 include Jumonji and
AT-rich interacting domain 2 (Peng et al., 2009), PHD finger pro-
tein 19, and AE binding protein 2 (Hyun et al., 2017). Structural
elucidation of PRC2 revealed an intricate network of protein-pro-
tein interactions between EED, EZH2, and SUZ12, which are
necessary for PRC2 catalytic activity (Jiao and Liu, 2015; Justin
et al., 2016; Kasinath et al., 2018; Poepsel et al., 2018). Specif-
ically, EED recognition of H3K27me3 via itsWD40 domain serves
to stabilize the stimulation responsive motif of EZH2 and alloste-
rically activates the SET domain of EZH2 for trimethylation of
H3K27 on adjacent nucleosomes (Justin et al., 2016).
PRC2 has been reported as both an oncogene and suppressor
of tumorigenesis in an assortment of cancer types (Gan et al.,
2018). EZH2, EED, and SUZ12 are commonly upregulated in
certain cancers such as breast, colorectal, and prostate cancer
(Liu et al., 2015; Gan et al., 2018). Overexpression of EZH2 and
elevated levels of H3K27me3 have been linked to both increased
cell proliferation and chemotherapy resistance, which can result
in low survival rates. EED, EZH2, and SUZ12 are also susceptible
to mutations in cancer. For example, EZH2 gain-of-function mu-
tations are commonly associated with lymphomas. Heterozy-
gous EZH2 gain-of-function mutations in the C-terminal SET
domain occur at Y641, A677, and A687, and lead to EZH2
hyperactivity, an increase in global H3K27me3 levels, and
aberrant gene repression (Veneti et al., 2017). Diffuse large B
cell lymphomas (DLBCL) commonly harbor these mutations,
marking EZH2 as an important target for therapeutic intervention
(McCabe et al., 2012).
Effective inhibition of PRC2 catalytic activity has been
achieved by targeting both EED and EZH2. While initial efforts
were focused on developing inhibitors of the catalytic SET
Figure 1. Chemical Structures of UNC6852
and UNC7043
(A) UNC6852 is a bivalent chemical degrader of
PRC2 containing an EED ligand (green) and a VHL
ligand (coral).
(B) UNC7043 is a corresponding inactive control
compound which contains a cis-hydroxyproline
amino acid, abrogating binding to VHL.domain of EZH2 (Genta et al., 2019), it was recently demon-
strated that small-molecule antagonists of the EED WD40 
domain could phenocopy EZH2 inhibitors due to the critical 
role of EED in regulating PRC2 activity (He et al., 2017; Qi 
et al., 2017). EED and EZH2 inhibition have each been shown 
to reduce global H3K27me3 levels and result in anti-proliferative 
effects in EED and EZH2 wild-type cancer cell lines, as well as 
cell lines with EZH2 gain-of-function mutations (Xu et al., 2015; 
He et al., 2017; Shortt et al., 2017; Lee et al., 2018). EZH2 inhib-
itors that bind the SET domain include chemical probes such as 
UNC1999, as well as several compounds in clinical development 
including GSK126, EPZ-6438 (Tazemostat), CPI-1205, and DS-
3201b (Valemostat), which have been particularly effective in 
lymphomas with activating EZH2 mutations (McCabe et al., 
2012; Konze et al., 2013; Dilworth and Barsyte-Lovejoy, 2019; 
Genta et al., 2019). More recently, EED chemical probes 
EED226 and A-395 were reported, and currently MAK683, an 
analog of EED226, is in the clinic for similar applications (He 
et al., 2017; Huang et al., 2017; Dilworth and Barsyte-Lovejoy, 
2019). Resistance to EZH2 inhibitors has been observed in the 
clinic and is one limitation to this class of SAM-competitive mol-
ecules; however, EED antagonists have the potential to over-
come this acquired resistance (Brooun et al., 2016; Lee et al., 
2018). Overall, targeting PRC2 for cancer treatment has been 
shown to be an effective strategy, yet new approaches are 
needed to overcome observed resistance to EZH2 inhibitors 
and to develop novel therapeutics.
Bivalent chemical protein degraders, otherwise known as 
PROTACs, are molecules designed to degrade a specific endog-
enous protein of interest (POI) by harnessing the E3 ubiquitin 
ligase pathway (Cromm and Crews, 2017; Salami and Crews, 
2017). Bivalent protein degraders are composed of a ligand for 
the desired POI, an E3 ligase ligand, and an optimized linker con-
necting the two ligands. The most extensively used E3 ligase re-
cruiting ligands include VH032 and pomalidomide, which are 
responsible for recruitment of von Hippel-Lindau (VHL) as part 
of the CRL2VHL E3 ubiquitin ligase complex and cereblon 
(CRBN) as part of the CRL4CRBN E3 ubiquitin ligase complex, 
respectively (Fischer et al., 2014; Cardote et al., 2017; Cromm 
and Crews, 2017). The linker region typically consists of a flexible 
alkyl or polyethylene glycol (PEG) moiety, although other linkers 
have been explored. These bifunctional molecules bring the POI 
into close proximity with the E3 ligase recruiting protein to form aternary complex, which allows the E3
ligase Cullin ring complex to ubiquitylate a
lysine residue on the POI, thereby tagging
the protein for proteasomal degradation
(Gadd et al., 2017). Positive cooperativity
of ternary complex formation betweenthese proteins and the subsequent ubiquitylation of an available
lysine are both important factors for efficient proteasomal degra-
dation. In addition, chemical degraders act catalytically, which
compensates for their inherently low cell permeability (Bondeson
et al., 2015; Riching et al., 2018). Because they are catalytic and
do not require very high affinity for their POI, bivalent chemical
degraders have the potential to facilitate degradation of previ-
ously ‘‘undruggable’’ targets and represent a promising thera-
peutic strategy. Just recently, the first PROTAC entered the clinic
for the treatment of metastatic castration-resistant prostate can-
cer (Mullard, 2019), demonstrating that the anticipated pharma-
cokinetic challenges due to their high molecular mass can be
overcome. Because of the availability of ligands for both EZH2
and EED, we postulated that the development of bivalent de-
graders could be an effective alternative strategy to inhibit
PRC2 function.
Here, we describe the design, synthesis, and evaluation of a
PRC2 bivalent chemical degrader based on the potent EED
ligand EED226, which effectively degrades EED, EZH2, and
SUZ12 in a VHL-dependent fashion, reduces H3K27me3 levels,
and decreases proliferation of DB and Pfeiffer cells, which
are DLBCL cell lines harboring EZH2-activating mutations.
Together, these results demonstrate the feasibility of developing
PRC2-targeted degraders to block PRC2 function, to interrogate
PRC2 biology, and as potential therapeutics.
RESULTS
Design and Synthesis of EED-Targeted Bivalent
Degraders
Based upon the successful development of potent ligands for
EED, which function as allosteric inhibitors of PRC2 and the
emerging field of bivalent chemical degraders, we designed
and synthesized a series of heterobifunctional EED-targeted
chemical degraders. These compounds comprise an analog of
a known EED ligand, EED226, and VH032-amine, a ligand which
has been successfully employed in numerous examples for
CRL2VHL recruitment (Figure 1) (Frost et al., 2016; Qi et al.,
2017; An and Fu, 2018; Zou et al., 2019). We first needed to iden-
tify an exit vector on EED226 that would be synthetically
amenable to functionalization with a linker moiety without a sig-
nificant loss in potency. A crystal structure of EED226 bound to
the WD40 domain of EED indicated that the sulfone moiety of
Table 1. Analysis of the Extent of EED Binding and Degradation with Six EED-Targeted Degraders
Compound
= Linker
EED IC50 (nM) EED Degradation (%)
UNC6851 275 ± 2.55 47 ± 0.026
UNC6852 247 ± 2.90 80 ± 0.035
UNC6853 368 ± 56.0 24 ± 0.060
UNC6845 82 ± 3.8 0.03 ± 0.102
UNC6846 613 ± 73.8 0.04 ± 0.103
UNC6847 241 ± 0.778 29 ± 0.087
EED IC50 values were determined by TR-FRET and are reported as the average of two biological replicates ± SD. EED degradation (%) was evaluated in
HeLa cells dosed with 5 mM compound for 24 h. Results were quantified based on western blot analysis in Figures S3C and S3D. EED percent degra-
dation is reported as the average of two biological replicates ± SD.EED226 is solvent exposed, providing a potential site for func-
tionalization (PDB: 5GSA; Qi et al., 2017). VHL ligands have
several known functionalization sites based on their previous
incorporation into bivalent degraders providing multiple possible
exit vectors. Importantly, the exit vector chosen can have a
large impact on ternary complex formation (Cromm and Crews,
2017; Chan et al., 2018; Smith et al., 2019). Functionalization
off of the terminal amine of VH032 has been extensively used
in the design of bivalent degraders so we chose this position
for linker appendage (Frost et al., 2016; Chan et al., 2018;
Girardini et al., 2019). To connect the two ligands, different
length alkyl (UNC6851-UNC6853) and PEG linkers (UNC6845-
UNC6847) were incorporated to assess the distance required
to induce successful EED degradation upon formation of the
EED-degrader-VHL ternary complex (Table 1) (Cyrus et al.,
2011). To enable this approach, we synthesized a carboxylic
acid functionalized EED ligand via a Suzuki-Miyaura reaction
with (4-(methoxycarbonyl)phenyl)boronic acid and 8-bromo-
N-(furan-2-ylmethyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine (1)
and subsequent basic hydrolysis to yield (2) (Scheme S1).
VH032-amine (3) was reacted with the various N-Boc alkyl and
PEG linkers followed by deprotection (4–9). Assembly of the finalcompounds was achieved by an amidation reaction to afford
UNC6851, UNC6852, UNC6853, UNC6845, UNC6846, and
UNC6847 (Scheme S2).
Initially we confirmed that our bivalent molecules still potently
bound to the WD40 domain of EED via a time-resolved fluores-
cence resonance energy transfer (TR-FRET) assay. In this assay
we used 6XHis-tagged recombinant EED (residues 1–441) and
a biotinylated EED ligand previously developed in our lab
(UNC5114-biotin; Barnash et al., 2017), which were conjugated
to a fluorophore-labeled anti-6XHis antibody (acceptor) and
europium-labeled streptavidin (donor), respectively. EED226
was used as a positive control and displayed potencies compa-
rable with literature reported values (Figure S1, half maximal
inhibitory concentration [IC50] = 45 nM; reported IC50 = 22 nM)
(Huang et al., 2017). We also synthesized a negative control
EED ligand, UNC5679, which showed no significant binding
within the concentrations tested and is greater than 200-fold
less potent than EED226 (Figure S1, IC50 = >10 mM; reported
IC50 = 20.49 mM) (Huang et al., 2017). Alkyl-linked compounds
UNC6851, UNC6852, and UNC6853 showed a 6-, 5.5-, and
8-fold loss in potency compared with EED226, respectively.
PEG linked compounds UNC6845, UNC6846, and UNC6847
Figure 2. UNC6852 Degrades PRC2 Components EED, EZH2,
and SUZ12 in HeLa Cells
(A) Western blot analysis of PRC2 components following UNC6852
treatment in a dose-response fashion (0–30 mM, 24 h).
(B) Western blot analysis of PRC2 components following treatment of
UNC6852 (10 mM) from 2 to 72 h. Data are representative of at least two
biological replicates. Quantification of these results are reported in
Figure S4.revealed a 2-, 14-, and 5-fold loss in potency, respectively. Over-
all, these data confirm that our bivalent molecules are sufficiently 
potent binders of the WD40 domain of EED, and therefore should 
be able to engage EED as the first step in initiating the E3 ligase-
mediated proteasomal degradation pathway.
UNC6852 Mediates PRC2 Degradation
Next, we sought to assess the ability of our six bivalent mole-
cules to enable EED degradation. To do so, we first performed 
extensive antibody validation studies utilizing overexpression 
systems to identify EED and EZH2 antibodies that were both 
compatible with the Jess system for automated protein analysis 
(ProteinSimple) and suitable for follow-up studies (Figure S2). 
HeLa lysates were then generated from cells treated with biva-
lent degraders (5 mM) for 4, 24, and 48 h and screened on the 
Jess system (Figures S3A and S3B), which allows for the analysis 
of protein degradation in a more high-throughput fashion than 
traditional western blotting experiments. Due to the close prox-
imity of EZH2 residues to the EED226 binding site, we specu-
lated that EED226-derived degraders may additionally facilitateEZH2 degradation, and therefore both EED and EZH2 pro-
tein levels weremonitored. Encouragingly, these data sug-
gested that UNC6851 and UNC6852 resulted in a
decrease in the levels of both EED and EZH2 at 24 h,
with UNC6852 having a more pronounced effect than
UNC6851 at shorter and longer time points (4 and 48 h;
Figures S3A and S3B). These compounds differ by a single
CH2 group in the linker, with UNC6851 containing a
2-methylene linker and UNC6852 a 3-methylene linker.
In contrast, significant degradation was not observed
with UNC6853, which contains a slightly longer 4-methy-
lene linker, highlighting that even minor variations in a
linker moiety can significantly affect degradation effi-
ciency. The bivalent molecules with PEG linkers
(UNC6845, UNC6846, and UNC6847), all of which are
longer than the 4-methylene linker of UNC6853, were simi-
larly unable to alter the levels of EED or EZH2 under these
conditions. To validate these results, we performed tradi-
tional western blot analysis, evaluating EED and EZH2
protein levels after treatment with each of the six de-
graders for 24 h. UNC6852 was again identified as the
most proficient degrader of EED (80% degradation; Table
1; Figures S3C and S3D) and EZH2 (76%) under these
conditions.
To further investigate the degradation potential of
UNC6852, we evaluated EED and EZH2 levels upon treat-
ment with UNC6852 in a dose-response format at 24 h and
over various times at a fixed concentration (10 mM) bywest-
ern blot analysis (Figures 2 and S4). Upon treatment ofHeLa cells with UNC6852, no cellular toxicity was observed at
concentrations up to 30 mM. UNC6852 was capable of degrading
EED and EZH2 to varying extents at different concentrations and
time points. EED and EZH2 degradation occurred at similar con-
centrations of UNC6852, with half maximal degradation concen-
tration (DC50) values (the concentration atwhich 50%degradation
was observed) of 0.79 ± 0.14 and 0.3 ± 0.19 mM, respectively (Fig-
ures S4B and S4G). The maximal degradation observed (Dmax)
was slightly higher for EED (92%) than EZH2 (75%) and, interest-
ingly, EED was also degraded at earlier time points than EZH2,
with apparent half-lives (t1/2) of 0.81 ± 0.30 and 1.92 ± 0.96 h,
respectively (Figures S4A and S4G).
SUZ12 is the third core component of PRC2, and thus
we were equally interested in determining if UNC6852 can
effectively degrade SUZ12. In the dose-response and time
course studies described above, we found that SUZ12 was
degraded by UNC6852 but to a lesser extent than both EED
and EZH2 (Figures 2 and S4). We were unable to calculate
the DC50 and half-life for SUZ12 due to a maximal degradation
of only 22%.
Figure 3. PRC2 Components Are Not Degraded upon Treatment with Proteasome Inhibitors or Negative Control Compound UNC7043
(A) Western blot analysis of PRC2 components upon treatment of HeLa cells with UNC6852 and negative control compound UNC7043 (10 mM for 24 h).
(B) Western blot analysis of PRC2 components in HeLa cells pre-treated with proteasome inhibitors MLN4924 (1 mM for 7 h), Carfilzomib, and MG-132 (5 mM for
4.5 h), followed by UNC6852 4 h at 10 mM. Data are representative of at least two biological replicates.UNC6852 Facilitates PRC2 Degradation via VHL
Recruitment
To confirm that UNC6852 is facilitating degradation of PRC2 via
the ubiquitin-proteasomal degradation pathway induced by
CRL2VHL E3 ligase recruitment, we utilized proteasome inhibitors
and an inactive heterobifunctional control compound (UNC7043,
Figure 1). We designed and synthesized UNC7043, which is
structurally identical to UNC6852 except that it contains the
opposite enantiomer at the hydroxyproline moiety on the VHL
ligand (Scheme S2). This subtle change to VH032 disables ligand
binding to VHL, and hence when incorporated into a bivalent
molecule no longer recruits VHL. As expected, UNC7043 treat-
ment did not degrade EED, EZH2, or SUZ12 when HeLa cells
were dosed at 10 mM for 24 h (Figure 3A). This result further es-
tablished that UNC6852-mediated degradation of PRC2 is
occurring via the CRL2VHL-based ubiquitin-proteasomal degra-
dation pathway.
Inaddition, pre-treatmentwithproteasome inhibitorsMLN4924,
Carfilzomib, and MG-132 before addition of UNC6852 effectively
blocked EED and EZH2 degradation, again confirming the pro-
posed degradation mechanism (Figure 3B). Specifically, HeLa
cells were pre-treated for 7 h with MLN4924 (Pevonedistat) and
4.5 h with Carfilzomib or MG-132 to halt cellular ubiquitylation
mechanisms before addition of UNC6852 for 4 h. Degradation ef-
fects could not be evaluated at longer time points due to the
toxicity inherent to these proteasome inhibitors (Maniaci et al.,
2017; Huang et al., 2018). While it has been previously reported
that proteasome inhibitor treatment can decrease endogenous
EZH2 levels, treatment of HeLa cells with proteasome inhibitors
alone did not change EZH2 levels under these conditions (Rizq
et al., 2017).
UNC6852 Selectively Degrades EED and EZH2
To assess the effects of UNC6852 treatment on cellular protein
levels more broadly, we performed global proteomics experi-ments using tandem mass tag quantification comparing HeLa
cells treated with UN6852 (10 mM, 24 h) with DMSO-treated
control cells. Whole proteome analysis resulted in the
identification of >60,000 peptides corresponding to 5,452
quantifiable proteins. Notably, these data revealed that EED
and EZH2 were selectively degraded by UNC6852 within the
proteome (Figure 4). Significant degradation was defined by a
p value of <0.01 and a log2 fold change ratio of 0.5
(UNC6852-treated/DMSO-treated). Although SUZ12 did not
meet these criteria (log2 fold change = 0.34), modest
SUZ12 degradation (21%) was observed, which is consistent
with our previously determined Dmax value via western blot
analysis (Dmax = 22%; Figure S4). In addition, we were inter-
ested in evaluating the ability of UNC6852 to degrade EZH1
due to its significant sequence homology with EZH2; however,
EZH1 was not identified in the proteomics analysis, presumably
due to low levels of EZH1 expression as we were also unable to
detect EZH1 by western blot. Overall, this confirms that
UNC6852 selectively degrades PRC2 via the E3 ligase ubiqui-
tylation pathway.
UNC6852 Reduces H3K27me3 Levels and DLBCL Cell
Proliferation
We next sought to investigate the effects of PRC2 degradation
on H3K27me3 levels and cellular proliferation. We first treated
HeLa cells with UNC6852, EED226, and UNC1999, a potent
EZH1/2 inhibitor, over a time course of 24–72 h at 10 mM to
monitor H3K27me3 levels by western blot. As expected,
UNC6852 resulted in a decrease in protein levels of both EED
and EZH2 over these time points, whereas EED226 and
UNC1999 had no effect (Figure S5A). Importantly, UNC6852,
EED226, and UNC1999 led to a comparable decrease in
H3K27me3 levels, with H3K27me3 reduced by 51%, 52%, and
60%, respectively, after 72 h (Figures S5A and S5B). As com-
plete loss of H3K27me3 has previously been shown take up to
Figure 4. UNC6852 Selectively Degrades PRC2
Quantitative proteomics results showing relative abundance of proteins in 
HeLa cells treated with DMSO, UNC6852, or UNC7043 (10 mM, 24 h). Of the 
total 5,452 quantifiable proteins, EED and EZH2 were selectively degraded by 
UNC6852 within the proteome. Significant degradation was defined by a p 
value of <0.01 and a log2 fold change ratio of 0.5 (UNC6852-treated/DMSO-
treated). Data shown are three replicates measured in a single 10-plex tandem 
mass tag experiment.5 to 7 days upon treatment with PRC2 inhibitors, we observed a 
further decrease in H3K27me3 levels after 96 h of treatment with 
UNC6852 (Figures S5C and S5D).
Next, we were interested in evaluating the sensitivity of DLBCL 
cell lines that contain heterozygous EZH2 missense mutations to 
UNC6852. These gain-of-function mutations in the catalytic SET 
domain including EZH2Y641N and EZH2A677G lead to an increase 
in H3K27me3 levels due to PRC2 hyperactivity (Xu et al., 2015). 
First, we investigated the effect of UNC6852 on PRC2 degrada-
tion in DB cells (EZH2Y641N) in a dose-dependent manner at 24 h 
(Figures 5A and S4). We observed degradation of EED and 
EZH2/EZH2Y641N in DB cells (DC50 = 0.61 ± 0.18 and 0.67 ± 
0.24 mM, respectively), resulting in similar DC50 values as in 
HeLa cells. In contrast to previous results in HeLa cells where 
we observed partial degradation, EZH2/EZH2Y641N and EED 
were both completely degraded by UNC6852 (Dmax = 96% and 
94%, respectively). In addition, SUZ12 was also degraded to a 
much larger extent in DB cells. The maximal degradation of 
SUZ12 was 3.7-fold higher (Dmax = 82%) than in HeLa cells, 
with a calculated DC50 value of 0.59 ± 0.17 mM. As expected, 
treatment with UNC7043 in DB cells did not affect the levels of 
these proteins (Figure 5B). Degradation of PRC2 by UNC6852 
in DB cells also significantly reduced H3K27me3 levels, with a 
71% loss of H3K27me3 after 72 h (Figures 5C and 5D). To ensure 
that UNC6852 functions similarly in DLBCL lines with different 
missense mutations, we also treated Pfeiffer cells (EZH2A677G) 
with UNC6852 and similarly observed degradation of all three 
PRC2 subunits (Figure S6). Overall, UNC6852 potently degrades 
the core components of PRC2 and results in a concomitant loss 
of H3K27me3 in DLBCL cells with EZH2 gain-of-function 
mutations.
Furthermore, when DB and Pfeiffer cells were treated with 
UNC6852 for up to 12 days, robust anti-proliferative effectswere observed (Figures 6A–6C). Cells were similarly treated
with EED226 or UNC1999, both of which have been shown
to effectively reduce DLBCL cell proliferation (McCabe et al.,
2012; Konze et al., 2013; Huang et al., 2017; Yuan et al.,
2018). UNC6852 displayed a concentration-dependent inhibi-
tion of cell proliferation, similar to EED226 and UNC1999, with
a half maximal effective concentration (EC50) of 3.4 ± 0.77 mM
after 9 days in DB cells and 0.41 ± 0.066 mM after 6 days in
Pfeiffer cells (Figures 6D, S7C, and S7E). In addition, overall
cell toxicity was significantly less with UNC6852 (95% viable
cells) compared with EED226 (67% viable cells) and
UNC1999 (67% viable cells) in DB cells after 12 days (Fig-
ure S7A). In contrast, Pfeiffer cell viability was affected upon
treatment with UNC6852, EED226, and UNC1999 (Figure S7B).
This is not surprising as EZH2 inhibition and short hairpin
RNA-mediated knockdown has been previously shown to
lead to profound cytotoxic responses in Pfeiffer cells driven
by caspase-mediated apoptosis (McCabe et al., 2012). Inter-
estingly, the negative control compound UNC7043, which is
unable to bind VHL, had no effect on cell proliferation despite
containing a potent EED ligand (Figures 6A–6C). This result re-
affirms that the difference in proliferative effects between
EED226 and UNC7043 in DLBCL cells is likely due to the
lack of permeability inherent to most bivalent degraders and
that catalytic degradation is required for efficacy. Concor-
dantly, it can be concluded that the anti-proliferative effects
seen with UNC6852 are due to PRC2 degradation as opposed
to EED inhibition alone.
DISCUSSION
Here, we report our discovery of an EED-targeted bivalent
chemical degrader (Hsu et al., 2020). We show that UNC6852
potently binds EED in vitro, degrades EED and other PRC2 com-
ponents in a highly selective fashion, inhibits PRC2 catalytic ac-
tivity resulting in decreased H3K27me3 levels, and has anti-pro-
liferative effects in DLBCL cell lines. We demonstrate that
UNC6852 effectively degrades PRC2 components EED, EZH2,
and SUZ12 via VHL recruitment and the E3 ligase proteasome
degradation pathway.
To achieve efficient degradation, productive ternary complex
formation with EED and VHL, as well as subsequent ubiquityla-
tion of an available lysine residue, are essential. In common
with other chemical degraders, we found that the linker incor-
porated to bridge the EED and VHL ligands was critical.
UNC6852 contains a short alkyl linker of only three methylene
groups, and we were surprised to find that the addition of a
fourth methylene group (UNC6853) was sufficient to substan-
tially reduce EED degradation, confirming the sensitivity of
this system to the spatial proximity and orientation of the two
ligands. As a relatively small set of potential EED degraders
was evaluated in this study, ongoing efforts are aimed at deter-
mining the ‘‘sweet-spot’’ for optimal linking within this ligand
pair and establishing broader structure-degradation relation-
ships to optimize the degradation efficiency of this class of
molecules.
Although UNC6852 contains a potent and selective ligand
for EED to mediate EED degradation, we were pleased to
find that EZH2 was potently degraded in a parallel fashion,
Figure 5. UNC6852 Degrades PRC2 and Re-
duces H3K27me3 Levels in EZH2Y641N DB
cells
(A) Western blot analysis of the degradation of EED,
EZH2, and SUZ12 in DB cells containing a hetero-
zygous EZH2Y641N mutation treated with UNC6852
(0.1–30 mM for 24 h).
(B) Western blot analysis following treatment of DB
cells with UNC6852 or negative control compound
UNC7043 (10 mM for 24 h).
(C) Western blot analysis of PRC2 components
and H3K27me3 in DB cells treated with UNC6852
in a time-dependent fashion (10 mM for 24, 48,
and 72 h).
(D) Quantification of H3K27me3 levels relative to
total H3 in (C). DMSO control was normalized to 1.
Data are representative of at least two biological
replicates. Data are represented as mean ± SD.and SUZ12 to a somewhat lesser extent in multiple cell lines.
This phenomenon of a bivalent degrader not only degrading
its intended target, but an entire protein complex is quite
unique. This result was confirmed by both western blot exper-
iments as well as more extensive global proteomics studies,
which also revealed the exquisite selectivity of UNC6852-
mediated degradation within the proteome. It has been known
for some time that EZH2 is not catalytically active in isolation,
and recent structural studies have revealed that EZH2, EED,
and SUZ12 associate intimately, and that the interactions
between these three subunits seem to closely regulate
enzymatic activity (Jiao and Liu, 2015). Specifically, EED is
engulfed by a belt-like structure of EZH2, and SUZ12
contacts both of these two subunits. As a result, EZH2 is posi-
tioned in very close proximity to the EED226 binding site.
Mechanistically, it is possible that UNC6852 mediates the
direct ubiquitylation of EED, EZH2, and SUZ12. Alternatively,
ubiquitylation of one of the three PRC2 components may
result in the entire complex being recruited to the proteasome
for degradation due to the close association and intertwined
nature of the three proteins. It is also conceivable that some
combination of these two mechanisms contributes to overall
PRC2 degradation, because EED, EZH2, and SUZ12 are not
all degraded to the same extent under identical conditions.
We observed that SUZ12, which is somewhat further from
the EED226 binding site in PRC2, is degraded to a lesserextent than both EED and EZH2, sug-
gesting that PRC2 is not consistently re-
cruited to the proteasome as a single
unit. Overall, these mechanistic ques-
tions are challenging to tease apart but
they are of high interest in conceptual-
izing the degradation of protein com-
plexes more broadly.
Due to the genetic data linking PRC2 to
tumorigenesis, extensive efforts have led
to the development of numerous clinical
candidates that target the SET domain of
EZH2, as well as more recently the
WD40 domain of EED. However, it hasbeen reported that resistance to SAM-competitive EZH2
inhibitors can be caused by single-point mutations in cell culture
(Baker et al., 2015; Gibaja et al., 2016), suggesting that patients
may become refractory to this class of molecules. Targeted pro-
tein degradation as a therapeutic approach is unique in that it is
more likely to prevent the evolution of target-directed resistance
mechanisms, and recent excitement over this approach to drug
discovery cannot be overstated. As a result, we were motivated
to investigate small-molecule-induced PRC2 degradation as an
additional approach to targeting PRC2, particularly in the
context of human cancer cell lines that are sensitive to EZH2
and EED inhibition. We demonstrate that UNC6852 has compa-
rable anti-proliferative effects with EZH2 and EED inhibitors
(UNC1999 and EED226, respectively) in DB and Pfeiffer cells.
We can attribute the effect observedwith UNC6852 to PRC2 cat-
alytic degradation versus on target inhibition because the nega-
tive control compound UNC7043, which potently binds EED
in vitro but does not engage VHL, has no effect. Importantly,
the cell toxicity observed in DB cells with UNC6852 was sub-
stantially less than with both EED and EZH2 inhibitors, further
supporting the notion that PRC2 degraders may have specific
advantages over existing inhibitors in some cases. In summary,
the results presented in this study demonstrate that PRC2-tar-
geted degradation can be achieved and is a viable approach
to potently and selectively inhibit PRC2 function. UNC6852 is a
useful tool compound to further interrogate PRC2 function in
Figure 6. UNC6852 Decreases Cell Prolifera-
tion in EZH2 Mutant DLBCL Cell Lines
(A) Proliferation effects on DB cells upon treatment
with EED226, UNC1999, UNC6852, and UNC7043
(3 mM) reported relative to DMSO treatment. Cor-
responding cell viability data are shown in Fig-
ure S7A.
(B) Proliferation effects on Pfeiffer cells upon treat-
ment with EED226, UNC1999, UNC6852, and
UNC7043 (3 mM) reported relative to DMSO treat-
ment. Corresponding cell viability data are shown in
Figure S7B.
(C) Quantification of proliferation effects shown in
(A and B) at day 6 and 9 time points.
(D) UNC6852 displays a concentration-dependent
inhibition of DB cell proliferation after 9 days of
treatment (0.5–10 mM, half maximal effective con-
centration [EC50] = 3.4 ± 0.77 mM) and Pfeiffer cell
proliferation after 6 days of treatment (0.1–5 mM,
EC50 = 0.41 ± 0.066 mM). Corresponding cell viability
data are shown in Figures S7D and S7F. Data are
represented as the mean of three biological
replicates ± SD (A–D).development and disease, as well as for further development 
into potential therapeutics.SIGNIFICANCE
The misregulation of PRC2 due to EZH2 overexpression or 
EZH2 gain-of-function mutations is prevalent in oncogen-
esis. Despite the growing number of EZH2 inhibitors in 
the clinic, inhibitor resistance through subsequent EZH2 
mutations and chemoresistance is still a concern and new 
therapeutic approaches are clearly needed. Using an EED-
targeted bivalent chemical degrader (UNC6852), we demon-
strate the successful degradation of all core PRC2 compo-
nents including EED, EZH2, and SUZ12. PRC2 degradation 
leads to a loss in PRC2 catalytic activity, a decrease in 
H3K27me3 levels, and anti-proliferative effects in DLBCL 
cell lines with EZH2 gain-of-function mutations. Importantly, 
the anti-proliferative effects of UNC6852 are comparable 
with those of potent inhibitors of EZH2 and EED. UNC6852 
provides a unique tool for studying PRC2 function and 
downregulation of PRC2 activity in cancer. In addition, 
PRC2-targeted degraders may have the ability to overcome 
acquired resistance to EZH2 small-molecule inhibitors and 
provide a complementary therapeutic strategy to com-
pounds currently in clinical development.STAR+METHODS
Detailed methods are provided in the online version of this paper 
and include the following:d KEY RESOURCES TABLE
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Polyclonal Sheep IgG Anti-EED R&D Systems Cat # AF5827; RRID: AB_2246350
Monoclonal Rabbit IgG Anti-EZH2 (D2C9) XP Cell Signaling Technology Cat # 5246S; RRID: AB_10694683
Monoclonal Rabbit IgG Anti-SUZ12 (D39F6) XP Cell Signaling Technology Cat # 3737S; RRID: AB_2196850
Rabbit Polyclonal to HA tag Abcam Cat # ab9110; RRID: AB_307019
Monoclonal Mouse Anti-GAPDH-AlexaFluor 680 Abcam Cat # ab184095
Polyclonal Chicken Anti-GAPDH EMD Millipore Cat # AB2302; RRID: AB_10615768
IR Dye 680RD Secondary Antibody Goat
anti-mouse IgG (H+L)
LI-COR Cat # 926-68070; RRID: AB_10956588
IR Dye 680RD Secondary Antibody Goat
anti-rabbit IgG (H+L)
LI-COR Cat # 926-68071; RRID: AB_10956166
IR Dye 800CW Secondary Antibody Goat
anti-rabbit IgG (H+L)
LI-COR Cat # 926-32211; RRID: AB_621843
Polyclonal Donkey anti-rabbit IgG (H+L) HRP LifeTech/Novex Cat # A16035; RRID: AB_2534709
Polyclonal Goat anti-chicken IgY (H+L) HRP LifeTech/Novex Cat # A16054; RRID: AB_2534727
Polyclonal Donkey anti-sheep IgG (H+L) HRP LifeTech/Novex Cat # A16041; RRID: AB_2534715
LANCE Ultra ULight anti-6X-histidine antibody Perkin Elmer Cat # TRF0105
Biological Samples
pCMVHA EED wild type plasmid Addgene (Bracken et al., 2003) Cat # 24231; RRID: Addgene_24231
pCMVHA hEZH2 plasmid Addgene (Bracken et al., 2003) Cat #24230; RRID: Addgene_24230
Chemicals, Peptides, and Recombinant Proteins
Recombinant EED (residues1 – 441) Purified in house (Barnash et al., 2017) Accession number: AAD08714
Lance Eu-W1024 Streptavidin Perkin Elmer Cat # AD0062
Experimental Models: Cell Lines
Human: HeLa ATCC Cat # CCL-2
Human: DB (EZH2Y641N mutation) ATCC Cat # CRL-2289
Human: 293T ATCC Cat # CRL-11268
Human: Pfeiffer ATCC Cat # CRL-2632
Software and Algorithms
GraphPad Prism Software Prism https://www.graphpad.com/
ImageLab Software Bio-Rad http://www.bio-rad.com/en-us/product/
image-lab-software?ID=KRE6P5E8Z
ImageStudio Software LI-COR https://www.licor.com/bio/image-studio/
MaxQuant v1.6.3.4. Computational Systems BioChemistry -
Max Planck Institute of Biochemistry
https://www.maxquant.org/maxquant/
Perseus Computational Systems BioChemistry -
Max Planck Institute of Biochemistry
https://www.maxquant.org/perseus/
Other
EnVision 2103 Multilabel Plate Reader ParkinElmer N/A
TC20 Cell counter Bio-Rad N/A
Chemidoc Imager Bio-Rad N/A
Odyssey Imager LI-COR N/A
Jess Protein Simple https://www.proteinsimple.com/jess.html
Deposited Data
Multiplexed global proteome analysis with
TMT quantitation
ProteomeXchange (Vizcaino et al., 2013) PXD016021
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for reagents should be directed to and will be fulfilled by the Lead contact, Lindsey I. James 
(ingerman@email.unc.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
HeLa Cell Culture Conditions
HeLa cells were obtained from ATCC (CCL-2) through the UNC Lineberger Tissue Culture Facility. Cells were cultured in MEM-a 1X 
(Gibco, 12571071), 1% MEM Non-essential amino acid solution (Sigma, M7145), and 10% FBS (VWR Seradigm, 89510-194). Cells 
were maintained in a humidified incubator at 37C, 5% CO2.
DB Cell Culture Conditions
DB cells were obtained from ATCC (CRL-2289) through the UNC Lineberger Tissue Culture Facility. Cells were cultured in RPMI 
1640 (Gibco, 11-875-093) and 10% FBS. Cells were maintained in a humidified incubator at 37C, 5% CO2.
Pfeiffer Cell Culture Conditions
Pfeiffer cells were obtained from ATCC (CRL-2632) through the UNC Lineberger Tissue Culture Facility. Cells were cultured in RPMI 
1640 (Gibco, 11-875-093) and 10% FBS. Cells were maintained in a humidified incubator at 37C, 5% CO2.
293T Cell Culture Conditions
293T cells were obtained from ATCC (CRL-11268). Cells were cultured in DMEM (Gibco, 11995-065), 1% pen/strep, and 10% FBS. 
Cells were maintained in a humidified incubator at 37C, 5% CO2.
METHOD DETAILS
Protein Expression and Purification
Full length EED (reference sequence AAD08714) was expressed with an N-terminal His-tag in a pET28 vector. The pET28-EED 
expression construct was transformed into Rosetta2 BL21(DE3)pLysS competent cells (Novagen, EMD Chemicals, San Diego, 
CA). Protein expression was induced by growing cells at 37C with shaking until the OD600 reached 0.6-0.8 at which time the tem-
perature was lowered to 15C and expression was induced by adding 0.1 mM IPTG and continuing shaking overnight. Cells were 
harvested by centrifugation and pellets were stored at -80C.
His-tagged EED protein was purified by resuspending thawed cell pellets in 30 ml of lysis buffer (50 mM sodium phosphate pH 7.2, 
150 mM NaCl, 30 mM imidazole, 1X EDTA free protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN)) per liter of culture. 
Cells were lysed on ice by sonication with a Branson Digital 450 Sonifier (Branson Ultrasonics, Danbury, CT) at 40% amplitude for 12 
cycles with each cycle consisting of a 20 second pulse followed by a 40 second rest. The cell lysate was clarified by centrifugation 
and loaded onto a HisTrap FF column (GE Healthcare, Piscataway, NJ) that had been preequilibrated with 10 column volumes of 
binding buffer (50 mM sodium phosphate pH 7.2, 500 mM NaCl, 30 mM imidazole) using an AKTA FPLC (GE Healthcare, Piscataway, 
NJ). The column was washed with 15 column volumes of binding buffer and protein was eluted in a linear gradient to 100% elution 
buffer (50 mM sodium phosphate pH 7.2, 500 mM NaCl, 500 mM imidazole) over 20 column volumes. Peak EED containing fractions 
were pooled and concentrated to less than 8 ml in Amicon Ultra-15 concentrators 10 kDa molecular weight cut-off (Merck Millipore, 
Carrigtwohill Co. Cork IRL). Concentrated protein was loaded onto a HiLoad 26/60 Superdex 200 prep grade column (GE Healthcare, 
Piscataway, NJ) that had been preequilibrated with 1.2 column volumes of sizing buffer (25 mM Tris pH 7.5, 500 mM NaCl, 2 mM DTT, 
5% glycerol) using an ATKA FPLC (GE Healthcare, Piscataway, NJ). Protein was eluted isocratically in sizing buffer over 1.3 column 
volumes at a flow rate of 2 ml/min collecting 3 ml fractions. Peak fractions were analyzed for purity by SDS-PAGE and those con-
taining pure protein were pooled and concentrated using Amicon Ultra-15 concentrators 10 kDa molecular weight cut-off (Merck 
Millipore, Carrigtwohill Co. Cork IRL). Concentrated EED protein was dialyzed into a buffer containing 25 mM Tris, pH 7.5, 
250 mM NaCl, 2 mM DTT, 5% glycerol for storage.
Time Resolved-Fluorescence Energy Transfer Assay
The TR-FRET assay was developed and performed as previously reported (Rectenwald et al., 2019). Briefly, assays were run using 
white, low-volume, flat-bottom, nonbinding, 384-well microplates (Greiner, 784904) containing a total assay volume of 10 mL per well. 
The assay buffer was composed of 20 mM Tris [pH 7.5], 150 mM NaCl, 0.05% Tween 20, and 2 mM DTT. LANCE Europium (Eu)-
W1024 Streptavidin conjugate (2 nM) and LANCE Ultra ULight-anti-6x-His antibody (10 nM) were used as donor and acceptor flu-
orophores associated with the tracer ligand and protein, respectively. Final assay concentrations of 15 nM 6X histidine tagged EED 
protein (residues 1-441, N-terminal tag) and 15 nM of UNC5114-biotin tracer ligand were used for final compound testing. Assay per-
formance was evaluated using the Z’ factor calculation at varying DMSO concentrations up to 3%. Low signals were obtained using 
50 mM EED226 to obtain complete inhibition and high signals were obtained without compound. The Z’ factor was consistent at each 
DMSO concentration revealing a DMSO tolerance of up to 3% (Z’ 0.5% = 0.83, Z’ 3% = 0.80).
A 10 point, three-fold serial dilution of each compound at 100X final assay concentration was made in DMSO using a TECAN 
Freedom EVO liquid handling workstation to create an assay mother plate. The top concentration of each compound in the mother
plate was 1 mM. Using a TTP Labtech Mosquito HTS liquid handling instrument, assay ready plates were stamped with 100 nL of
the compound solutions from the mother plate. 10 mL of a mixture consisting of EED, UNC5114-biotin, and the fluorophore reagents
(concentrations noted above) was added to each well of an assay ready plate using aMultidrop Combi (ThermoFisher). After addition
of assay components, plates were sealed with clear covers, mixed gently on a tabletop shaker for 1 minute, centrifuged at 1000xg for
2 minutes, and allowed to equilibrate in a dark space for 1 hour. After 1 hour, the plate was read on an EnVision 2103 Multilabel Plate
Reader (PerkinElmer) using an excitation filter at 320 nm and emission filters at 615 and 665 nm. Emission signals (615 and 665 nm)
were measured simultaneously using a dual mirror D400/D630 (using a 100-microsecond delay). TR-FRET output signal was ex-
pressed as emission ratios of acceptor/donor (665/615 nm) counts. Percent inhibition was calculated on a scale of 0% (i.e., activity
with DMSO vehicle only) to 100% (100 mM EED226) using full column controls on each plate. The data was fit with a four-parameter
nonlinear regression analysis using GraphPad Prism to determine IC50 values and are reported as an average of two biological
replicates ± standard deviation.
Cell Dosing and Lysis
For degradation analysis, cells were cultured in 6 well plates (Olympus Genesee Scientific, 25-105) and dosed with the appropriate
concentration of bivalent degrader from a DMSO stock. Adherent cells (HeLa) were seeded at 400,000 cells/well for 24 hr analysis
and 100,000 cells/well for 72 hr analysis. At the appropriate time point, cells were washed with 2X PBS, scraped in PBS (1mL), centri-
fuged, aspirated, and lysed in 40-50 mL of modified RIPA lysis buffer (1X Modified RIPA buffer (25 mM Tris pH 8, 150 mM NaCl, 1 %
NP-40, 1 % sodium deoxycholate, 0.1 % SDS), 1X Protease inhibitor cocktail (Active Motif, 37490), 4mL/mL Benzonase nuclease
(Millipore, R90% SDS page, E1014), DPBS (Gibco)). Non-adherent cells (DB and Pfeiffer) were seeded at 800,000 cells/well for
24 hr analysis, and 100,000 cells/well for 72 hr analysis. Cells were centrifuged, aspirated, washed with 2X PBS, and aspirated again
and lysed in 40-50 mL of Cytobuster lysis buffer (Cytobuster (71009), 1X Protease inhibitor cocktail (Active Motif, 37490), 2mL/mL
Benzonase nuclease (Millipore, R90% SDS page, E1014)).
The protein levels were quantified using PierceDetergent Compatible Bradford Assay Kit (Thermo Scientific, 23246) for themodi-
fied RIPA lysis buffer, and with Protein Assay Dye Reagent Concentrate (Bio-Rad, 5000006) using a known concentration of BSA
standard for the Cytobuster lysis buffer.
Jess Protein Simple Analysis
Jess Protein Simple was used according to product guideline instructions. HeLa cell were treated with bivalent degraders UNC6851,
UNC6852, UNC6853, UNC6845, UNC6846, UNC6847 at 5 mM for 4, 24, and 48 hrs, and cell lysates were generated using a modified
RIPA buffer. Cell lysates were used at 1mg/mL. The primary antibodies usedwere: anti-EED (1:10, R&DSystems, AF5827), anti-EZH2
(1:100, D2C9 XP, Cell Signaling Technology, 5246S). The secondary antibodies used were: anti-sheep HRP secondary antibody
(1:25, LifeTech/Novex, A16041), anti-rabbit secondary IR antibody (1:20, Protein Simple, 043-820).
Western Blot Analysis
Cell lysate (20 mg) was combined with Laemmli buffer (Bio-Rad; 2X - 1610737 or 4X - 1610747) containing 2-mercaptoethanol (5%)
and samples were boiled at 95C prior to gel loading. Gels (15mL, 15 well; 4-15% precast mini-PROTEAN TGX gels, Bio-Rad,
4561046DC; or 4-15%precast mini-PROTEAN TGX Stain Free gels, Bio-Rad 4568086) were placed in aMini-PROTEAN tetra
cell at 200V in 1X Tris/Gycine/SDS running buffer (Bio-Rad, 1610772). Molecular weight ladder’s used were either Precision Plus
Protein Dual Color Standard (Bio-Rad, 161-0374), or PageRuler Plus pre-stained protein ladder (ThermoFisher, 26619). Protein
was transferred onto Immobilon-FL PVDF Membranes (Millipore Sigma, IPFL00010), with 1X Tris/Gycine transfer buffer (Bio-Rad,
1610772) andmethanol (0.2% volume) at 100V for 1 hr at 4C.Membranes were blocked at room temperature for 1 hr with Odyssey
blocking buffer (TBS, LI-COR, 926-31099), and the incubated with primary antibodies overnight at 4C.
Primary Antibodies
anti-EED (1:500, R&D Systems, AF5827), anti-EZH2 (1:1000, D2C9 XP Cell Signaling Technology, 5246S), anti-SUZ12 (1:500,
D39F6 XP Cell Signaling Technology, 3737S), anti-GAPDH-AlexaFluor 680 (1:5000, Abcam, ab184095), anti-GAPDH (1:5000,
EMD Millipore, AB2302), anti-H3K27me3 (1:2000, Abcam, ab6002), anti-Histone H3 (1:5000, Abcam, ab1791), anti-HA (Abcam,
1:500, ab9110).
Membranes were incubated with the corresponding secondary antibodies for 1hr at room temperature prior to imaging. Fluores-
cence imaging was performed on a LI-COR Odyssey. For chemiluminescent detection, membranes were activated with ECL Prime
western blotting detection reagent (Amersham, RPN2232) and imaged on a Bio-Rad Chemidoc.
Li-COR Fluorescent Secondary Antibodies
IR Dye 680RD (1:10000, Goat anti-mouse, LI-COR, 926-68070), IR Dye 800CW (1:10000, Goat anti-rabbit, LI-COR, 926-32211).
Chemi-Doc Chemiluminescent Secondary Antibodies
Goat anti-chicken HRP (1:10000, LifeTech/Novex, A16054), Donkey anti-sheep HRP (1:10000, LifeTech/Novex, A16041), Donkey
anti-rabbit HRP (1:10000, LifeTech/Novex, A16035).
Western Blot Quantification
Western blots were analysed by firstly calculating the densitometry on either ImageStudio software or ImageLab software for LI-
COR or Chemidoc imaging, respectively. The densitometry of the protein of interest band relative to the densitometry of each
corresponding GAPDH band was calculated. The resulting densitometry relative to the DMSO band was calculated to give the %
degradation.
For the dose response and time study these values were plotted in GraphPad Prism against the corresponding concentration or 
time of degrader treatment. An inhibitor concentration vs response (three parameters) regression was plotted and the IC50 values 
were taken from GraphPad Prism which corresponded to either the apparent half-life (t1/2, when protein levels were plotted against 
time), or the half maximal degradation concentration (DC50, when protein levels were plotted against concentration). The maximal 
degradation (Dmax) was calculated based on the % degradation at 30 mM after 24 hours).
Cell Proliferation Analysis
Exponentially growing DB cells were seeded in a 12 well plate (Corning Costar, CLS3513) at a cell density of 0.5 3 105 cells/mL 
and exponentially growing Pfeiffer cells were seeded at a cell density of 1.0 3 105 cells/mL. Every 3 days the media was exchanged, 
cells were split back to the seeding density, and the compound or DMSO control were re-dosed. At each time point the cells were 
counted on an automated Bio-Rad TC20 cell counter with Trypan blue (Abcam, ab233465) and cell counting slides (1450015) to 
give the cell count (cells/mL) and cell viability (%). The % cell proliferation is calculated based on the total cell number expressed 
as split-adjusted viable cells, relative to the DMSO control at the same time point. To determine an EC50, the total cell number is ex-
pressed as a split-adjusted viable cells/mL and the results were analyzed in GraphPad Prism with a log(inhibitor) vs response - var-
iable slope (four parameters). EC50 values and are reported as an average of three biological replicates ± standard deviation.
Antibody Validation Methods
pCMVHA EED WT (Addgene plasmid # 24231 ; http://n2t.net/addgene:24231; RRID:Addgene_24231) and pCMVHA hEZH2 (Addg-
ene plasmid # 24230; http://n2t.net/addgene:24230 ; RRID:Addgene_24230) were a gift from Kristian Helin.(Bracken et al., 2003) 
Constructs were confirmed by sequencing prior to use. pCMVHA EED WT contains the DNA sequence to express the two smaller 
isoforms of EED (EED3/4) but not the two larger predicted isoforms EED1/2 (Montgomery et al., 2007). Two individually isolated plas-
mids from the original bacterial streak received from Addgene were transfected into 293T cells using Fugene HD (Promega) per man-
ufacturer’s protocol. Cells were collected two days post transfection and assayed by western blot using anti-HA (Abcam, ab9110, 
1:1500) to confirm protein expression. For validation of EED antibody AF5827 (R&D Systems) and EZH2 antibody CST5246 (Cell 
Signaling Technology), the same plasmids were transfected into HeLa cells using Fugene HD and cell lysates analyzed by western 
blot using the respective antibodies relative to untransfected controls. Blots are provided overexposed to see endogenous levels of 
EED and EZH2 in untransfected controls as well as overlaid on membrane to allow for comparison to the ladder (PageRuler Plus Pre-
stained Protein Ladder, 10-250kDa, ThermoFisher). GAPDH (Millipore, AB2302, 1:5000) is provided as a loading control for all 
samples.
Global Proteomics Experiments
Exponentially growing HeLa cells were seeded in 10 cm plates and treated with UNC6852, UNC7043, or DMSO (10 mM, 24 hrs). Cells 
from biological triplicates were harvested on ice and centrifuged at 4C for 10 min. Lysis on ice with 8M urea in 50 mM Tris-HCl pH 7.8 
with 1X protease inhibitor cocktail (Active Motif, 37490) and 1X phosphatase inhibitor (Roche, PhosSTOP, 05892791001). Sample 
preparation: Each sample (200 mg) was incubated with trypsin overnight. Samples were desalted with SepPak C18 cartridges 
(Waters, 100 mg sorbent, WAT036820), and Pierce BCA peptide quantitation assay was performed. Each sample (50 mg) was labelled 
with a TMT label. After labelling, samples were quenched and combined 1:1 into a single multiplexed sample. An aliquot (100 mg) of 
the mixed sample was fractionated into 8 fractions using the Pierce high pH reversed phase fractionation spin columns. Peptide frac-
tions were analysed in duplicate by LC-MS/MS using a Thermo Easy nLC 1200-QExactive HF. Proteins were identified by searching 
raw data against a reviewed Uniprot human database (containing 20,245 sequences) using Andromeda and quantified using TMT 
intensities within MaxQuant v1.6.3.4. Further data analysis was performed in Perseus, Excel, and GraphPad Prism. Statistical sig-
nificance between each pair of groups was calculated using Student’s T-test and a p-value of <0.01 was used as the significance 
cut-off. Log2 fold change of each protein was calculated by dividing the averaged log2 TMT intensities of each compound by the 
averaged log2 TMT intensities of the DMSO control across all replicates. A log2 absolute fold change of 0.5 was used as the signif-
icance cut-off.
Synthesis of Compound Intermediates and Final Compounds
General Chemistry Procedures
All reagents and solvents were obtained from commercial suppliers and were used without further purification unless otherwise 
stated. EED226 and UNC1999 were purchased from MedChemExpress, and UNC5679 (reported as compound 19) was synthesized 
according to literature procedures (Huang et al., 2017). Reactions were carried out using conventional glassware and room temper-
ature was generally 22C. Reactions were carried out at elevated temperatures using a temperature regulated hot plater-stirrer. Thin 
layer chromatography was carried out using Merck silica plates coated with fluorescent indicator UV254. These were analysed under 
254 nm UV light. Analytical LCMS data for all compounds were acquired using an Agilent 6110 Series system with the UV detector set 
to 254 nm. Samples were injected (<10 mL) onto an Agilent Eclipse Plus 4.6 3 50 mm, 1.8 mm, C18 column at room temperature. 
Mobile phases A (H2O + 0.1% acetic acid) and B (MeOH + 0.1% acetic acid) were used with a linear gradient from 10% to 100%
B in 5.0 min, followed by a flush at 100% B for another 2 minutes with a flow rate of 1.0 mL/min. Mass spectra (MS) data were 
acquired
in positive ion mode using an Agilent 6110 single quadrupole mass spectrometer with an electrospray ionization (ESI) source. Normal
phase column chromatography was performedwith a Teledyne Isco CombiFlashRf 200 using RediSepRf SILICA columnswith the
UV detector set to 254 nm and 280 nm. Reverse phase column chromatography was performedwith a Teledyne Isco CombiFlashRf
200 using C18 RediSepRf Gold columnswith the UV detector set to 220 nm and 254 nm. Preparative HPLCwas performed using an
Agilent Prep 1200 series with the UV detector set to 220 nm and 254 nm. Samples were injected onto either a Phenomenex Luna
250 3 30 mm (5 mm) C18 column or a Phenomenex Luna 75 x 30 mm (5 mm) C18 column at room temperature. Analytical LCMS
(at 254 nm) was used to establish the purity of targeted compounds. All compounds that were evaluated in biochemical and biophys-
ical assays had >95% purity as determined by LCMS.
Analysis of Products
1H and 13C NMR spectra were obtained on a Bruker AV 400 at 400 MHz, 101 MHz respectively. Chemical shifts are reported in ppm
and coupling constants are reported in Hz with CDCl3 referenced at 7.26 (
1H) and 77.1 ppm (13C), DMSO-d6 referenced at 2.50 (
1H)
and 39.5 ppm (13C), and MeOD-d4 referenced at 3.31 (
1H) and 49.0 ppm (13C).
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Prepared according to literature procedures (Huang et al., 2017). To a flask containing 5-bromo-4-chloro-2-(methylthio)pyrimidine
(500mg, 2.09mmol, 1.0 equiv) in ethanol (10mL), was added hydrazinemonohydrate (340mg, 4.39mmol, 2.1 equiv) and the reaction
was stirred at room temperature for 2 hrs. The reaction was filtered under vacuumwith hexane to yield the desired product as a white
solid E-5-bromo-4-hydrazineylidene-2-(methylthio)-4,5-dihydropyrimidine (484 mg, 99%).
1H NMR (MeOD-d4, 400 MHz): d 8.89 (s, 1H), 3.26 (s, 3H).
13C NMR (MeOD-d4, 101 MHz): d 178.6, 167.5, 163.9, 106.7, 23.3.
LCMS: expected mass for [M+H]+ (C5H7BrN4S), 234.96 m/z; found, 235.05 m/z.
8-bromo-5-(methylthio)-[1,2,4]triazolo[4,3-c]pyrimidine (13).
Prepared according to literature procedures (Huang et al., 2017). To a flask was added E-5-bromo-4-hydrazineylidene-2-(meth-
ylthio)-4,5-dihydropyrimidine (2.21 g, 9.39 mmol, 1.0 equiv), and triethoxymethane (1.39 g, 1.56 mL, 9.39 mmol, 1.0 equiv) and
the reaction was heated to reflux (140C) for 4 h. The reaction was cooled to room temperature and the crude material concentrated
in vacuo and purified by column chromatography (silica, 0-100% EtOAc in hexane) to yield the desired product as a white solid
8-bromo-5-(methylthio)-[1,2,4]triazolo[4,3-c]pyrimidine (1.64 g, 71%).
1H NMR (CDCl3, 400 MHz): d 8.84 (s, 1H), 8.00 (s, 1H), 2.80 (s, 3H).
13C NMR (CDCl3, 101 MHz): d 149.0, 147.4, 141.6, 133.9, 102.6, 14.1.
LCMS: expected mass for [M+H]+ (C6H5BrN4S), 244.94 m/z; found, 245.00 m/z.
8-bromo-N-(furan-2-2-ylmethyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine (1).
Prepared according to literature procedures (Huang et al., 2017). To a flask was added furan-2-ylmethanamine (24.6 mL,
278.0 mmol, 41.6 equiv) and 8-bromo-5-(methylthio)-[1,2,4]triazolo[4,3-c]pyrimidine (1.6g, 6.7 mmol, 1.0 equiv) and stirred at
room temperature for 2 hr. The reaction was concentrated in vacuo almost to dryness and filtered under vacuum with CH2Cl2
(50 mL) to yield the desired product as a white solid 8-bromo-N-(furan-2-2-ylmethyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine
(1.57 g, 80%).
1H NMR (DMSO-d6, 400 MHz): d 9.44 (s, 1H), 7.82 (s, 1H), 7.61 (t, J = 1.4 Hz, 1H), 6.42 (d, J = 1.4 Hz, 2H), 4.68 (s, 2H).
13C NMR (DMSO-d6, 101 MHz): d 150.9, 147.8, 143.8, 143.2, 142.7, 134.0, 110.7, 108.1, 91.2, 38.0.
LCMS: expected mass for [M+H]+ (C10H8BrN5O), 293.99 m/z; found, 294.10 m/z.
4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzoic acid (2).
To an oven dried microwave vial was added (4-(methoxycarbonyl)phenyl)boronic acid (184 mg, 1.0 mmol, 1.5 equiv), 8-bromo-N-
(furan-2-ylmethyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine (200 mg, 680 mmol, 1.0 equiv), Pd(dppf)Cl2.CH2Cl2 (111 mg, 136 mmol, 0.2
equiv), and sodium bicarbonate (143 mg, 1.70 mmol, 2.5 equiv), and purged under N2. To the vial was added THF (4 mL), H2O (2 mL)
and heated to 110C for 18 hrs. The reaction was cooled to room temperature, filtered through celite with EtOAc, and purified by
column chromatography (silica, 0-100% EtOAc in hexane) to yield the intermediate methyl 4-(5-((furan-2-ylmethyl)amino)-[1,2,4]tri-
azolo[4,3-c]pyrimidin-8-yl)benzoate, which was used without further purification in the next step.
LCMS: expected mass for [M+H]+ (C18H15N5O3), 350.12 m/z; found, 350.10 m/z.
To the flask containing 4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzoate was added lithium hydroxide
(48.9 mg, 2.04 mmol, 3.0 equiv), THF (2.7 mL), H2O (0.5 mL) and heated to 50
C for 16 hrs. The reaction was cooled, THF concen-
trated in vacuo, and diluted with 1M HCl (200 mL). The organics were extracted with EtOAc (3 ˣ 200 mL), washed with brine (400 mL)
and dried with a phase separator to yield the desired product as a white solid 4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyr-
imidin-8-yl)benzoic acid (227 mg, 99% over two steps).
1H NMR (DMSO-d6, 400 MHz): d 9.64 (s, 1H), 9.26 (s, 1H), 8.30 (d, J = 8.7 Hz, 2H), 8.19 (s, 1H), 8.02 (d, J = 8.68 Hz, 2H), 7.63 – 7.62
(m, 1H), 6.45 – 6.42 (m, 2H), 4.78 (d, J = 5.4 Hz, 2H).
13C NMR (DMSO-d6, 101 MHz): d 167.1, 151.2, 148.3, 143.9, 142.5, 141.4, 137.9, 129.5, 129.2, 126.8, 110.6, 107.8, 37.7, 2 3 ar-
omatic C not observed (coincident).
(2S,4R)-1-((S)-3,3-dimethyl-2-((2,2,2-trifluoroacetyl)-l4-azaneyl)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-
2-carboxamide (3).
Compound 3 was synthesized as the TFA salt according to literature procedures (Buckley et al., 2015). Obtained 871 mg.
1H NMR (MeOD-d4, 400 MHz) d 9.01 (s, 1H), 7.49 – 7.40 (m, 4H), 4.67 (dd, J = 7.7, 9.5 Hz, 1H),4.58 – 4.52 (m, 2H), 4.36
(d, J = 15.5 Hz, 1H), 4.05 (s, 1H), 3.82 (d, J = 11.3 Hz, 1H), 3.71 (dd, J = 3.5, 11.2 Hz, 1H), 2.48 (s, 3H), 2.34 – 2.26 (m, 1H), 2.09
(ddd, J = 4.2, 9.6, 13.4 Hz, 1H), 1.13 (s, 9H).
13C NMR (MeOD-d4, 101 MHz) d 174.0, 168.6, 153.3, 148.3, 140.4, 133.8, 131.1, 130.4, 129.0, 71.2, 61.0, 60.4, 58.0, 43.7, 39.1,
35.8, 26.6, 15.5.
LCMS: expected mass for [M+H]+ (C22H30N4O3S), 431.20 m/z; found, 431.20 m/z.
(2S,4R)-1-((S)-2-(3-aminopropanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxa-
mide 2,2,2-trifluoroacetate (4).
To a flask was added 3-((tert-butoxycarbonyl)amino)propanoic acid (34.7 mg, 184 mmol, 1.0 equiv), DIPEA (0.10 mL, 588.00 mmol,
3.2 equiv), and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (77 mg, 239 mmol, 1.3 equiv) in DMF
(2 mL), followed by addition of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrroli-
dine-2-carboxamide (94.9 mg, 220 mmol, 1.0 equiv). The reaction was stirred at room temperature for 16 hrs, concentrated in vacuo
and purified by column chromatography (silica, 0-10%MeOH in CH2Cl2). The intermediate was N-Boc deprotected with 20% TFA in
CH2Cl2 (2 mL), concentrated in vacuo and purified by column chromatography (C18, 0-100%MeOH in H2O, 0.1% TFA). The product
was concentrated to yield the desired product as a clear gum (2S,4R)-1-((S)-2-(3-aminopropanamido)-3,3-dimethylbutanoyl)-4-hy-
droxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (100 mg, 88 %) over 2 steps.
1H NMR (MeOD-d4, 400 MHz): d 9.04 (s, 1H), 7.49 – 7.40 (m, 4H), 4.59 – 4.56 (m, 2H), 4.55 – 4.50 (m, 2H), 4.36 (d, J = 15.5 Hz, 1H),
3.98 (d, J = 11.1 Hz, 1H), 3.79 (dd, J = 3.8, 11.0 Hz, 1H), 3.23 – 3.10 (m, 2H), 2.69 (t, J = 6.4 Hz, 2H), 2.49 (s, 3H), 2.28 – 2.20 (m, 1H),
2.13 – 2.05 (m, 1H), 1.05 (s, 9H).
13C NMR (MeOD-d4, 101 MHz): d 174.4, 172.4, 172.1, 153.4, 148.0, 140.6, 134.0, 131.0, 130.3, 129.0, 71.2, 60.8, 59.5, 57.9, 43.7,
39.1, 37.0, 36.2, 32.3, 27.0, 15.4.
LCMS: expected mass for [M+H]+ (C25H35N5O4S), 502.24 m/z; found, 502.20 m/z.
(2S,4R)-1-((S)-2-(4-aminobutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxa-
mide 2,2,2-trifluoroacetate (5).
To a flaskwas added 4-((tert-butoxycarbonyl)amino)butanoic acid (19mg, 92 mmol, 1.0 equiv), DIPEA (51 mL, 0.29mmol, 3.2 equiv),
and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (38 mg, 0.12 mmol, 1.3 equiv) in DMF (0.9 mL),
followed by addition of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-
carboxamide (50mg, 92 mmol, 1.0 equiv). The reaction was stirred at room temperature for 16 hrs, concentrated in vacuo and purified
by column chromatography (silica, 0-10% MeOH in CH2Cl2). The reaction was telescoped into the deprotection with 20% TFA in
CH2Cl2 (2 mL), concentrated in vacuo and purified by column chromatography (C18, 0-100%MeOH in H2O, 0.1% TFA). The product
was concentrated to yield the desired product as a clear oil (2S,4R)-1-((S)-2-(4-aminobutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-
N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (31 mg, 53 %) over 2 steps.
1H NMR (MeOD-d4, 400 MHz): d 8.91 (s, 1H), 7.50 – 7.41 (m, 4H), 4.62 – 4.49 (m, 4H), 4.36 (d, J = 15.5 Hz, 1H), 3.92 (d, J = 11.1Hz,
1H), 3.80 (dd, J = 3.9, 11.0 Hz, 1H), 2.96 (t, J = 7.4 Hz, 2H), 2.47 (s, 3H), 2.47 – 2.41 (m, 2H), 2.26 – 2.19 (m, 1H), 2.13 – 2.04 (m, 1H),
1.96 – 1.87 (m, 2H), 1.04 (s, 9H).
13C NMR (MeOD-d4, 101 MHz): d 174.38, 174.36, 172.3, 153.0, 148.8, 140.3, 133.5, 131.4, 130.5, 130.3, 129.5, 129.0, 71.1, 60.8,
59.3, 58.0, 43.7, 40.4, 39.0, 36.4, 33.3, 27.0, 24.4, 15.7.
LCMS: expected mass for [M+H]+ (C26H37N5O4S), 516.26 m/z; found, 516.20 m/z.
(2S,4R)-1-((S)-2-(5-aminopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxa-
mide 2,2,2-trifluoroacetate (6).
To a flask was added 5-((tert-butoxycarbonyl)amino)pentanoic acid (25 mg, 0.12 mmol, 1.0 equiv), DIPEA (65 mL, 0.37 mmol, 3.2
equiv), and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (48 mg, 0.15 mmol, 1.3 equiv) in DMF
(1.0 mL), followed by addition of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrroli-
dine-2-carboxamide (50 mg, 0.12 mmol, 1.0 equiv). The reaction was stirred at room temperature for 16 hrs, concentrated in vacuo
and purified by column chromatography (silica, 0-10% MeOH in CH2Cl2). The reaction was telescoped into the deprotection with
20% TFA in CH2Cl2 (2 mL), concentrated in vacuo and purified by column chromatography (C18, 0-100% MeOH in H2O, 0.1%
TFA). The product was concentrated to yield the desired product as a clear oil (2S,4R)-1-((S)-2-(5-aminopentanamido)-3,3-dimethyl-
butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (41 mg, 55%) over 2 steps.
1H NMR (MeOD-d4, 400 MHz): d 9.06 (s, 1H), 7.49 – 7.39 (m, 4H), 4.62 – 4.50 (m, 4H), 4.37 (d, J = 15.5 Hz, 1H), 3.91 (d, J = 11.1Hz,
1H), 3.81 (dd, J = 3.9, 11.0 Hz, 1H), 2.93 (t, J = 6.5 Hz, 2H), 2.50 (s, 3H), 2.38 – 2.32 (m, 2H), 2.27-2.18 (m, 1H), 2.13 – 2.02 (m, 1H),
1.73 – 1.64 (m, 4H), 1.04 (s, 9H).
13C NMR (MeOD-d4, 101 MHz): d 175.2, 174.4, 172.4, 153.5, 147.9, 140.7, 134.1, 130.9, 130.4, 129.1, 71.1, 60.8, 59.2, 58.0, 43.7,
40.3, 39.0, 36.5, 35.5, 28.0, 27.0, 23.4, 15.3.
LCMS: expected mass for [M+H]+ (C27H39N5O4S), 530.27 m/z; found, 530.20 m/z.
(2S,4R)-1-((S)-2-(3-(2-(2-aminoethoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)
pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (7).
To a flask was added 2,2-dimethyl4-oxo-3,8,11-trioxa-5-azatetradecan-14-oic acid (100 mg, 1.15 mmol, 1.0 equiv), DIPEA
(0.20 mL, 1.15 mmol, 3.2 equiv) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (151 mg,
469 mmol, 1.3 equiv) followed by addition of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)
benzyl)pyrrolidine-2-carboxamide (155 mg, 361 mmol, 1.0 equiv). The reaction was stirred at room temperature for 16 hrs,
concentrated in vacuo and purified by column chromatography (silica, 0-10% MeOH in CH2Cl2). The reaction was telescoped into
the deprotection with 20% TFA in CH2Cl2 (2 mL), concentrated in vacuo and purified by column chromatography (C18, 0-100%
MeOH inH2O, 0.1%TFA). The product was concentrated to yield the desired product as a clear gum (2S,4R)-1-((S)-2-(3-(2-(2-amino-
ethoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-
trifluoroacetate (135 mg, 53 %) over 2 steps.
1H NMR (MeOD-d4, 400 MHz): d 9.08 (s, 1H), 7.52 – 7.41 (m, 4H), 4.64 (s, 1H), 4.60 – 4.49 (m, 3H), 4.39 (d, J = 15.5 Hz, 1H), 3.91
(d, J = 11.3 Hz, 1H), 3.81 (dd, J = 3.8, 11.0 Hz, 1H), 3.75 (t, J = 3.8, 11.0 Hz, 2H), 3.71 – 3.68 (m, 2H), 3.67 – 3.62 (m, 4H), 3.13 – 3.08
(m, 2H), 2.62 – 2.52 (m, 2H), 2.50 (s, 3H), 2.27 – 2.20 (m, 1H), 2.12 – 2.04 (m, 1H), 1.04 (s, 9H).
13C NMR (MeOD-d4, 101 MHz): d 174.4, 173.7, 172.3, 153.5, 147.9, 140.7, 134.1, 130.9, 130.5, 130.4, 129.5, 129.1, 71.31, 71.26,
71.1, 68.1, 67.8, 60.9, 59.1, 58.0, 43.7, 40.7, 39.1, 37.0, 36.7, 27.0, 15.3.
LCMS: expected mass for [M+H]+ (C29H43N5O6S), 590.29 m/z; found, 590.30 m/z.
(2S,4R)-1-((S)-14-amino-2-(tert-butyl)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrro-
lidine-2-carboxamide 2,2,2-trifluoroacetate (8).
To a flask was added 2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-oic acid (36 mg, 0.12 mmol, 1.0 equiv), DIPEA
(65 mL, 0.37 mmol, 3.2 equiv) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (48 mg, 0.15 mmol,
1.3 equiv) followed by addition of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrro-
lidine-2-carboxamide (50 mg, 0.12 mmol, 1.0 equiv). The reaction was stirred at room temperature for 16 hrs, concentrated in vacuo
and purified by column chromatography (silica, 0-10% MeOH in CH2Cl2). The reaction was telescoped into the deprotection with
20% TFA in CH2Cl2 (2 mL), concentrated in vacuo and purified by column chromatography (C18, 0-100% MeOH in H2O, 0.1%
TFA). The product was concentrated to yield the desired product as a clear gum (2S,4R)-1-((S)-14-amino-2-(tert-butyl)-4-oxo-
6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate
(23 mg, 27 %) over 2 steps.
1H NMR (MeOD-d4, 400 MHz): d 9.02 (s, 1H), 7.49 – 7.42 (m, 4H), 4.70 (s, 1H), 4.59 – 4.54 (m, 1H), 4.54 – 4.48 (m, 2H), 4.40 (d, J =
15.5 Hz, 1H), 4.08 (d, J = 2.0 Hz, 2H), 3.90 (d, J = 11.0 Hz, 1H), 3.81 (dd, J = 3.7, 11.0 Hz, 1H), 3.75 – 3.67 (m, 13H), 3.14 – 3.09 (m, 2H),
2.49 (s, 3H), 2.29 – 2.21 (m, 1H), 2.14 – 2.05 (m, 1H), 1.05 (s, 9H).
13C NMR (MeOD-d4, 400 MHz): d 174.3, 172.1, 171.9, 152.9, 140.2, 131.6, 130.5, 130.4, 129.5, 129.0, 72.0, 71.5, 71.3, 71.2, 71.1,
70.9, 67.9. 61.0, 58.4, 58.1, 43.7, 40.7, 39.0, 37.0, 27.0, 15.8.
LCMS: expected mass for [M+H]+ (C30H45N5O7S), 620.30 m/z; found, 620.30 m/z.
(2S,4R)-1-((S)-1-amino-17-(tert-butyl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)
benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (9).
To a flask was added 2,2-dimethyl-4-oxo-3,8,11,14,17,20,23-heptaoxa-5-azahexacosan-26-oic acid (100 mg, 220 mmol, 1.0
equiv), DIPEA (0.12 mL, 706 mmol, 3.2 equiv) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
(92 mg, 287 mmol, 1.3 equiv) followed by addition of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthia-
zol-5-yl)benzyl)pyrrolidine-2-carboxamide (94.9 mg, 220 mmol, 1.0 equiv). The reaction was stirred at room temperature for
16 hrs, concentrated in vacuo and purified by column chromatography (silica, 0-10%MeOH in CH2Cl2). The reaction was telescoped
into the deprotection with 20% TFA in CH2Cl2 (2 mL), concentrated in vacuo and purified by column chromatography (C18, 0-100%
MeOH inH2O, 0.1%TFA). The product was concentrated to yield the desired product as a clear gum (2S,4R)-1-((S)-1-amino-17-(tert-
butyl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
2,2,2-trifluoroacetate (92 mg, 42 %) over 2 steps.
1H NMR (MeOD-d4, 400 MHz): d 9.02 (s, 1H), 7.50 – 7.41 (m, 4H), 4.64 (s, 1H), 4.59 – 4.49 (m, 3H), 4.37 (d, J = 15.5 Hz, 1H), 3.90 (d,
J = 11.1 Hz, 1H), 3.80 (dd, J = 3.9, 11.0 Hz, 1H), 3.77 – 3.71 (m, 4H), 3.69 – 3.61 (m, 12H), 3.15 – 3.12 (m, 2H), 2.64 – 2.51 (m, 2H), 2.49
(s, 3H), 2.27 – 2.20 (m, 1H), 2.13 – 2.05 (m, 1H), 1.04 (s, 9H).
13C NMR (MeOD-d4, 101 MHz): d 174.4, 173.9, 172.2, 153.3, 148.2, 140.6, 133.9, 131.1, 130.5, 130.4, 129.4, 129.0, 71.39, 71.35,
71.3, 71.23, 71.22, 71.1, 70.9, 68.3, 67.8, 60.8, 59.1, 58.0, 43.7, 40.5, 39.0, 37.1, 36.7, 27.0, 15.5.
LCMS: expected mass for [M+H]+ (C33H51N5O8S), 678.35 m/z; found, 678.30 m/z.
(2S,4S)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-tri-
fluoroacetate (10).
Compound 10 was synthesized according to literature procedures (Frost et al., 2016). Obtained 44 mg.
1H NMR (MeOD-d4, 400 MHz) d 9.07 (s, 1H), 7.51 – 7.40 (m, 4H), 4.62 – 4.53 (m, 2H), 4.42 – 4.35 (m, 2H), 4.02 (s, 1H), 3.91 (dd, J =
5.3, 10.6 Hz, 1H), 3.63 (dd, J = 4.6, 10.5 Hz, 1H), 2.54 – 2.45 (m, 4H), 2.03 – 1.95 (m, 1H), 1.13 (s, 9H).
13C NMR (MeOD-d4, 101 MHz) d 174.3, 168.7, 153.5, 147.9, 140.4, 134.1, 131.0, 130.4, 129.1, 71.3, 61.1, 60.2, 57.2, 43.8, 37.9,
35.6, 26.7, 15.3.
LCMS: expected mass for [M+H]+ (C22H30N4O3S), 431.20 m/z; found, 431.20 m/z.
(2S,4S)-1-((S)-2-(4-aminobutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxa-
mide 2,2,2-trifluoroacetate (11).
To a flask was added 4-((tert-butoxycarbonyl)amino)butanoic acid (10.6 mg, 53 mmol, 1.1 equiv), DIPEA (27 mL, 154 mmol, 3.2
equiv), and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (20.1 mg, 63 mmol, 1.3 equiv) in DMF
(2 mL), followed by addition of (2S,4S)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrroli-
dine-2-carboxamide 2,2,2-trifluoroacetate (26.2 mg, 48 mmol, 1.0 equiv). The reaction was stirred at room temperature for 16 hrs,
concentrated in vacuo and purified by column chromatography (silica, 0-10%MeOH in CH2Cl2). The intermediate wasN-Boc depro-
tected with 20% TFA in CH2Cl2 (2 mL), concentrated in vacuo and purified by column chromatography (C18, 0-100%MeOH in H2O,
0.1% TFA). The product was concentrated to yield the desired product as a clear gum (2S,4S)-1-((S)-2-(4-aminobutanamido)-3,3-
dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (18 mg, 58 %)
over 2 steps.
1H NMR (MeOD-d4, 400 MHz): d 9.11 (s, 1H), 7.51 – 7.41 (m, 4H), 4.57 – 4.47 (m, 3H), 4.45 – 4.36 (m, 2H), 4.04 (dd, J = 5.1, 10.6 Hz,
1H), 3.71 (dd, J = 3.6, 10.4 Hz, 1H), 2.95 (t, J = 7.5 Hz, 2H), 2.47 (s, 3H), 2.47 – 2.39 (m, 3H), 2.04 – 1.96 (m, 1H), 1.95 – 1.86 (m, 2H), 1.05
(s, 9H).
13C NMR (MeOD-d4, 101 MHz): d 174.9, 174.6, 172.7, 153.7, 147.7, 140.6, 134.3, 130.9, 130.4, 129.2, 71.5, 61.1, 59.7, 57.6, 43.8,
40.4, 37.9, 35.9, 33.1, 27.0, 24.4, 15.2.
LCMS: expected mass for [M+H]+ (C26H37N5O4S), 502.25 m/z; found, 516.25 m/z.
(2S,4R)-1-((S)-2-(3-(4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzamido)propanamido)-3,3-dimethylbuta-
noyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (UNC6851).
To a flask was added 4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzoic acid (5 mg, 15 mmol, 1.0 equiv),
DIPEA (7.8 mL, 45 mmol, 3.0 equiv) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (6.2 mg,
19 mmol, 1.3 equiv) followed by addition (2S,4R)-1-((S)-2-(3-aminopropanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methyl-
thiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (9.2 mg, 15.00 mmol, 1.0 equiv). The reaction was stirred at
room temperature for 16 hrs, concentrated in vacuo and purified by preparative high-performance liquid chromatography (C18,
0-100% MeCN in H2O (0.1% TFA)) to yield the desired product as a white solid (3 mg, 27%).
1HNMR (MeOD-d4, 400MHz): d 9.06 (s, 1H), 8.04 (s, 1H), 7.97 – 7.91 (m, 4H), 7.48 (d, J = 1.7 Hz, 1H), 7.44 – 7.30 (m, 5H), 6.45 – 6.38
(m, 2H), 4.84 (s, 2H), 4.65 (s, 1H), 4.62 – 4.54 (m, 2H), 4.54 – 4.49 (m, 1H), 4.27 (d, J = 15.5 Hz, 1H), 3.97 (d, J = 10.4 Hz, 1H), 3.81 (dd,
J = 3.9, 11.0 Hz, 1H), 3.78 – 3.71 (m, 1H), 3.66 – 3.57 (m, 1H), 2.69 – 2.57 (m, 2H), 2.44 (s, 3H), 2.29 – 2.22 (m, 1H), 2.12 – 2.05 (m, 1H),
1.05 (s, 9H).
LCMS: expected mass for [M+H]+ (C42H46N10O6S), 819.33 m/z; found, 819.20 m/z.
(2S,4R)-1-((S)-2-(4-(4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzamido)butanamido)-3,3-dimethylbuta-
noyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (UNC6852).
To a flask was added 4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzoic acid (5 mg, 15 mmol, 1.0 equiv),
DIPEA (7.8 mL, 45 mmol, 3.0 equiv) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (6.2 mg,
19 mmol, 1.3 equiv) followed by addition (2S,4R)-1-((S)-2-(4-aminobutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methyl-
thiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (9.4 mg, 15 mmol, 1.0 equiv). The reaction was stirred at room
temperature for 16 hrs, concentrated in vacuo and purified by preparative high-performance liquid chromatography (C18,
0-100% MeCN in H2O (0.1% TFA)) to yield the desired product as a white solid (2 mg, 19%).
1H NMR (MeOD-d4, 400 MHz): d 9.35 (s, 1H), 9.05 (s, 1H), 8.12 (s, 1H), 7.99 – 7.94 (m, 4H), 7.50 – 7.40 (m, 5H), 6.48 – 6.38 (m, 2H),
4.86 (s, 2H), 4.63 (s, 1H), 4.62 – 4.55 (m, 1H), 4.55 – 4.49 (m, 2H), 4.34 (d, J = 15.6 Hz, 1H), 3.93 (d, J = 11.0 Hz, 1H), 3.82 (dd, J = 3.8,
10.9 Hz, 1H), 3.49 – 3.39 (m, 2H), 2.47 (s, 3H), 2.43 – 2.37 (m, 2H), 2.27 – 2.19 (m, 1H), 2.12 – 2.06 (m, 1H), 1.99 – 1.90 (m, 2H), 1.06
(s, 9H).
13C NMR (MeOD-d4, 101 MHz): d 175.4, 174.5, 172.4, 169.6, 160.6, 153.5, 152.0, 145.5, 145.3, 143.8, 140.7, 137.3, 135.1, 130.8,
130.3, 129.4, 129.0, 128.9, 128.8, 111.9, 111.6, 109.4, 71.1, 60.9, 59.3, 58.0, 43.7, 40.5, 39.4, 39.0, 36.5, 34.0, 27.1, 26.7, 15.3.
LCMS: expected mass for [M+H]+ (C43H48N10O6S), 833.35 m/z; found, 833.20 m/z.
(2S,4R)-1-((S)-2-(5-(4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzamido)pentanamido)-3,3-dimethylbuta-
noyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (UNC6853).
To a flask was added 4-(5-((furan-2-ylmethyl)amino)-[1,2,4]Striazolo[4,3-c]pyrimidin-8-yl)benzoic acid (5 mg, 15 mmol, 1.0 equiv),
DIPEA (7.8 mL, 45 mmol, 3.0 equiv) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (6.2 mg,
19 mmol, 1.3 equiv) followed by addition (2S,4R)-1-((S)-2-(5-aminopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methyl-
thiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (9.6 mg, 15 mmol, 1.0 equiv). The reaction was stirred at room
temperature for 16 hrs, concentrated in vacuo and purified by preparative high-performance liquid chromatography (C18,
0-100% MeCN in H2O (0.1% TFA)) to yield the desired product as a white solid (2 mg, 19 %).
1H NMR (MeOD-d4, 400 MHz): d 9.03 (s, 1H), 8.09 (s, 1H), 7.94 (ap s, 4H), 7.47 – 7.31 (m, 6H), 6.40 (dd, J = 2.6, 19.7 Hz, 2H), 4.61
(s, 1H), 4.58 – 4.52 (m, 1H), 4.51 – 4.46 (m, 2H), 4.32 (d, J = 15.7 Hz, 1H), 3.89 (d, J = 11.0 Hz, 1H), 3.79 (dd, J = 3.9, 10.9 Hz, 1H), 3.41
(t, J = 6.4 Hz, 2H), 2.45 (s, 3H), 2.37 – 2.31 (m, 2H), 2.23 – 2.17 (m, 1H), 2.10 – 2.03 (m, 1H), 1.73 – 1.62 (m, 4H), 1.02 (s, 9H), 23 H not
observed (under H2O peak).
LCMS: expected mass for [M+H]+ (C44H50N10O6S), 847.36 m/z; found, 847.20 m/z.
(2S,4R)-1-((S)-13-(tert-butyl)-1-(4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)phenyl)-1,11-dioxo-5,8-dioxa-
2,12-diazatetradecan-14-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (UNC6845).
To a flask was 4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzoic acid (10 mg, 30 mmol, 1.0 equiv), DIPEA
(16 mL, 90 mmol, 3.0 equiv) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (12.4mg, 39 mmol, 1.3
equiv) followed by addition of (2S,4R)-1-((S)-2-(3-(2-(2-aminoethoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-
(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (21 mg, 30 mmol, 1.0 equiv). The reaction was stirred
at room temperature for 16 hrs, concentrated in vacuo and purified by preparative high-performance liquid chromatography (C18,
0-100% MeCN in H2O (0.1% TFA)) to yield the desired product as a white solid (3 mg, 10 %).
1H NMR (MeOD-d4, 400MHz): d 9.35 (s, 1H), 9.07 (s, 1H), 8.14 (s, 1H), 7.96 (ap s, 4H), 7.50 – 7.47 (m, 1H), 7.47 – 7.37 (m, 4H), 6.46 –
6.37 (m, 2H), 4.66 (s, 1H), 4.57 (dd, J = 7.4, 15.2 Hz, 2H), 4.51 – 4.46 (m, 2H), 4.33 (d, J = 15.5 Hz, 1H), 3.89 (d, J= 11.2Hz, 1H), 3.79 (dd,
J = 3.8, 11.0 Hz, 1H), 3.75 – 3.58 (m, 10H), 2.53 – 2.43 (m, 4H), 2.21 (dd, J = 7.7, 13.2 Hz, 1H), 2.11 – 2.02 (m, 1H), 1.03 (s, 9H), 23Hnot
observed (under H2O peak).
LCMS: expected mass for [M+H]+ (C46H54N10O8S), 907.38 m/z; found, 907.20 m/z.
(2S,4R)-1-((S)-15-(tert-butyl)-1-(4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)phenyl)-1,13-dioxo-5,8,11-trioxa-
2,14-diazahexadecan-16-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (UNC6846).
To a flask was 4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzoic acid (5 mg, 15 mmol, 1.0 equiv), DIPEA
(8 mL, 45 mmol, 3.0 equiv) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (6.2 mg, 19 mmol,
1.3 equiv) followed by addition of (2S,4R)-1-((S)-14-amino-2-(tert-butyl)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-
(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (21 mg, 30 mmol, 1.0 equiv). The reaction was stirred
at room temperature for 16 hrs, concentrated in vacuo and purified by preparative high-performance liquid chromatography (C18, 0-
100% MeCN in H2O (0.1% TFA)) to yield the desired product as a white solid (4 mg, 30 %).
1H NMR (MeOD-d4, 400 MHz): d 9.36 (s, 1H), 9.11 (s, 1H), 8.16 (s, 1H), 7.97 – 7.91 (m, 4H), 7.50 – 7.48 (m, 1H), 7.48 – 7.39 (m, 4H),
6.47 – 6.37 (m, 2H), 4.69 (s, 1H), 4.58 (dd, J = 7.6, 15.2 Hz, 2H), 4.52 – 4.47 (m, 2H), 4.34 (d, J = 15.6 Hz, 1H), 4.03 – 3.88 (m, 3H),
3.80 (dd, J = 3.7, 10.9 Hz, 1H), 3.72 – 3.62 (m, 10H), 3.63 – 3.53 (m, 1H), 2.48 (s, 3H), 2.26 – 2.19 (m, 1H), 2.12 – 2.04 (m, 1H),
1.03 (s, 9H), 2 3 H not observed (under H2O peak).
LCMS: expected mass for [M+H]+ (C47H56N10O9S), 937.40 m/z; found, 937.20 m/z.
(2S,4R)-1-((S)-19-(tert-butyl)-1-(4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)phenyl)-1,17-dioxo-5,8,11,14-tet-
raoxa-2,18-diazaicosan-20-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (UNC6847).
To a flask was 4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzoic acid (10 mg, 30 mmol, 1.0 equiv), DIPEA
(16 mL, 90 mmol, 3.0 equiv) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (12.4mg, 39 mmol, 1.3
equiv) followed by addition of (2S,4R)-1-((S)-1-amino-17-(tert-butyl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-oyl)-4-hy-
droxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (24 mg, 30 mmol, 1.0 equiv). The reaction
was stirred at room temperature for 16 hrs, concentrated in vacuo and purified by preparative high-performance liquid chromatog-
raphy (C18, 0-100% MeCN in H2O (0.1% TFA)) to yield the desired product as a white solid (2 mg, 6 %).
1H NMR (MeOD-d4, 400 MHz): d 9.35 (s, 1H), 9.05 (s, 1H), 8.14 (s, 1H), 8.00 – 7.95 (m, 4H), 7.49 – 7.48 (m, 1H), 7.47 – 7.39 (m, 4H),
6.47 – 6.38 (m, 2H), 4.63 (s, 1H), 4.59 – 4.53 (m, 2H), 4.53 – 4.47 (m, 2H), 4.34 (d, J = 15.7 Hz, 1H), 3.88 (d, J = 11.0 Hz, 1H), 3.79 (dd, J =
3.8, 11.0 Hz, 1H), 3.73 – 3.54 (m, 17H), 2.58 – 2.50 (m, 1H), 2.48 (s, 3H), 2.46 – 2.40 (m, 1H), 2.24 – 2.17 (m, 1H), 2.12 – 2.01 (m, 1H), 1.02
(s, 9H) , 2 3 aliphatic H not observed (under H2O peak).
LCMS: expected mass for [M+H]+ (C50H62N10O10S), 995.44 m/z; found, [M/2+H]+ 498.30 m/z.
(2S,4S)-1-((S)-2-(4-(4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzamido)butanamido)-3,3-dimethylbuta-
noyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (UNC7043).
To a flask was 4-(5-((furan-2-ylmethyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)benzoic acid (10 mg, 30 mmol, 1.0 equiv), DIPEA (16 
mL, 90 mmol, 3.0 equiv) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (12.4 mg, 39 mmol, 1.3
equiv) followed by addition of (2S,4R)-1-((S)-1-amino-17-(tert-butyl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-oyl)-4-hy-
droxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (24 mg, 30 mmol, 1.0 equiv). The reaction
was stirred at room temperature for 16 hrs, concentrated in vacuo and purified by preparative high-performance liquid chromatog-
raphy (C18, 0-100% MeCN in H2O (0.1% TFA)) to yield the desired product as a white solid (4 mg, 18 %).
1H NMR (MeOD-d4, 400 MHz): d 9.35 (s, 1H), 9.09 (s, 1H), 8.14 (s, 1H), 7.97 (ap s, 4H), 7.49 – 7.38 (m, 5H), 6.47 – 6.36 (m, 2H), 4.56
(d, J = 15.5 Hz, 1H), 4.53 – 4.48 (m, 2H), 4.42 – 4.33 (m, 2H), 4.06 (dd, J = 5.1, 10.5 Hz, 1H), 3.70 (dd, J = 3.9, 10.5 Hz, 1H), 3.48 – 3.37
(m, 2H), 2.48 (s, 3H), 2.47 – 2.36 (m, 3H), 2.01 – 1.88 (m, 3H), 1.06 (s, 9H), 2 3 aliphatic H not observed (under H2O peak).
13C NMR (MeOD-d4, 101 MHz): d 175.7, 174.9, 172.7, 169.6, 160.4, 160.0, 153.6, 152.0, 145.7, 145.3, 143.8, 140.6, 139.0, 137.2,
135.1, 130.8, 130.4, 129.1, 128.9, 128.8, 111.7, 111.6, 109.4, 71.5, 61.0, 59.7, 57.6, 43.8, 40.5, 39.4, 37.9, 35.9, 33.8, 27.0, 26.7, 15.2.
LCMS: expected mass for [M+H]+ (C43H48N10O6S), 833.35 m/z; found, 833.25 m/z.
QUANTIFICATION AND STATISTICAL ANALYSIS
The method of determining error bars is indicated in the corresponding figure legend and biological replicate number is indicated.
Statistical significance for proteomics was calculated as outlined in the STAR Methods for Global Proteomics Analysis.
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